Michael Pishvaian, MD, PhD

No bio available.

Financial relationships

  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Seattle Genetics
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Tesaro
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Arcus Bio
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Ideaya
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Repare Tx
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Novartis
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Pfizer
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Merck
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Tizonia
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023
  • Attribution: 
    Other
    Type of financial relationship: 
    Grant Or Contract
    Ineligible company: 
    Biomed Valley Discoveries
    Topic: 
    Funding for my Institution
    Date added: 
    08/16/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond